Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib

Clinical trial NCT07486648 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07486648
Sponsor: Shanxi Province Cancer Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Lung Cancer (NSCLC)Lung Cancer (Non-Small Cell)Advanced Non-small-cell Lung Cancer

Start date: 2026-05-15
Primary completion: 2028-10-15
Enrollment: 53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.